Mirum Pharmaceuticals Raises Full-Year Guidance, In-licenses New FOP Drug with FDA Priority Review

summarizeSummary

Mirum Pharmaceuticals reported strong Q1 product sales and raised its full-year revenue guidance, while also announcing the in-licensing of zilurgisertib for FOP, which has received FDA Priority Review with a September PDUFA date.

check_boxKey Events

• Increased Full-Year Revenue Guidance

  Mirum raised its 2026 net product sales guidance to $660-$680 million, up from previous estimates, driven by strong Q1 sales of $159.9 million.

• Strategic In-licensing of Zilurgisertib

  The company acquired exclusive worldwide rights to zilurgisertib for Fibrodysplasia Ossificans Progressiva (FOP), paying an upfront fee of $16 million.

• FDA Priority Review for Zilurgisertib

  The New Drug Application (NDA) for zilurgisertib has been accepted by the FDA and granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026, indicating a potential new product launch this year.

• Significant Q1 Net Loss Due to IPR&D

  Mirum reported a Q1 net loss of $790.2 million, or $13.43 per share, primarily due to a non-recurring $726.3 million in-process research and development (IPR&D) expense from an acquisition.

auto_awesomeAnalysis

This 8-K provides a comprehensive business update alongside Q1 financial results. Despite a significant net loss driven by a non-recurring $726.3 million IPR&D expense related to an acquisition, the company demonstrated strong operational performance. Key positive drivers include a substantial increase in full-year revenue guidance to $660-$680 million, reflecting robust commercial momentum. Furthermore, the in-licensing of zilurgisertib, an ALK2 inhibitor for FOP, represents a significant pipeline expansion with a near-term catalyst, as it has received FDA Priority Review with a PDUFA date in September 2026. This strategic move positions Mirum for another potential product launch this year, reinforcing its leadership in rare genetic diseases. The market is likely to focus on these forward-looking growth drivers and pipeline advancements, outweighing the one-time accounting charge.